PT3381462T - Agente antiangiogénico e método de utilização de tal agente - Google Patents

Agente antiangiogénico e método de utilização de tal agente

Info

Publication number
PT3381462T
PT3381462T PT181685983T PT18168598T PT3381462T PT 3381462 T PT3381462 T PT 3381462T PT 181685983 T PT181685983 T PT 181685983T PT 18168598 T PT18168598 T PT 18168598T PT 3381462 T PT3381462 T PT 3381462T
Authority
PT
Portugal
Prior art keywords
agent
angiogenic
angiogenic agent
Prior art date
Application number
PT181685983T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Georgia State Univ Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia State Univ Research Foundation filed Critical Georgia State Univ Research Foundation
Publication of PT3381462T publication Critical patent/PT3381462T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70507CD2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT181685983T 2010-07-13 2011-07-13 Agente antiangiogénico e método de utilização de tal agente PT3381462T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36393310P 2010-07-13 2010-07-13

Publications (1)

Publication Number Publication Date
PT3381462T true PT3381462T (pt) 2022-07-22

Family

ID=44629339

Family Applications (2)

Application Number Title Priority Date Filing Date
PT181685983T PT3381462T (pt) 2010-07-13 2011-07-13 Agente antiangiogénico e método de utilização de tal agente
PT117385468T PT2593127T (pt) 2010-07-13 2011-07-13 Agente antiangiogénico e método de usar esses agente

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT117385468T PT2593127T (pt) 2010-07-13 2011-07-13 Agente antiangiogénico e método de usar esses agente

Country Status (12)

Country Link
US (2) US9175063B2 (enExample)
EP (2) EP2593127B1 (enExample)
JP (2) JP6353654B2 (enExample)
CN (1) CN103002904B (enExample)
AU (5) AU2011279155B2 (enExample)
CA (1) CA2804753C (enExample)
DK (1) DK2593127T3 (enExample)
ES (2) ES2674409T3 (enExample)
HU (1) HUE040205T2 (enExample)
PL (1) PL2593127T3 (enExample)
PT (2) PT3381462T (enExample)
WO (1) WO2012009471A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002904B (zh) * 2010-07-13 2017-01-18 乔治亚州立大学研究基金会 抗血管生成药剂及使用这种药剂的方法
FI3265482T3 (fi) * 2015-03-06 2026-01-16 Univ Georgia State Res Found Integreeniin kohdistuva proteiini ja menetelmä sen käyttämiseen
CN110317264B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物
CN108148117A (zh) * 2017-12-26 2018-06-12 张艳雪 一种抗菌肽的蛋白质结构特性及其研究方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JP4596916B2 (ja) * 2002-09-05 2010-12-15 メディミューン,エルエルシー Cd2拮抗薬を投与することによりt細胞悪性腫瘍を予防または治療する方法
BRPI0507404A (pt) * 2004-02-06 2007-06-26 Astellas Us Llc método de tratamento de um indivìduo que tem psorìase e kit
JP5377965B2 (ja) * 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
WO2009146099A2 (en) * 2008-04-02 2009-12-03 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
JP5792066B2 (ja) * 2008-09-08 2015-10-07 ホフマン/バーレット, リミテッド ライアビリティ カンパニー ポルフィラジン並びに光学的及びデュアル光学的/mrコントラスト並びに治療薬
CN103002904B (zh) * 2010-07-13 2017-01-18 乔治亚州立大学研究基金会 抗血管生成药剂及使用这种药剂的方法

Also Published As

Publication number Publication date
ES2923430T3 (es) 2022-09-27
EP2593127A1 (en) 2013-05-22
ES2674409T3 (es) 2018-06-29
AU2023202513A1 (en) 2023-05-11
JP2013534538A (ja) 2013-09-05
AU2019202174B2 (en) 2020-11-26
AU2011279155B2 (en) 2017-03-09
PL2593127T3 (pl) 2018-11-30
PT2593127T (pt) 2018-07-06
EP2593127B1 (en) 2018-05-30
HUE040205T2 (hu) 2019-02-28
EP3381462A1 (en) 2018-10-03
US20130281357A1 (en) 2013-10-24
WO2012009471A1 (en) 2012-01-19
CN103002904A (zh) 2013-03-27
JP6353654B2 (ja) 2018-07-04
US9175063B2 (en) 2015-11-03
CA2804753A1 (en) 2012-01-19
JP2016175913A (ja) 2016-10-06
AU2021201207A1 (en) 2021-03-11
EP3381462B1 (en) 2022-06-08
DK2593127T3 (en) 2018-07-02
CN103002904B (zh) 2017-01-18
US20160090408A1 (en) 2016-03-31
AU2019202174A1 (en) 2019-04-18
US11578114B2 (en) 2023-02-14
CA2804753C (en) 2021-05-25
AU2017201133A1 (en) 2017-03-09
AU2011279155A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
SG2014010706A (en) Method and composition
GB201016001D0 (en) Composition and method
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
SG11201404930SA (en) Post-cmp removal using compositions and method of use
SG11201504022RA (en) Glutamase inhibitors and method of use
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
ZA201207937B (en) Sarms and method of use thereof
EP2555860A4 (en) DIRECTED MULTIPORT EJECTOR AND USE METHOD THEREFOR
GB201122195D0 (en) Composition and method
GB2503842B (en) Composition and method of manufacture
GB201408236D0 (en) Composition and method
SG10201707813YA (en) Cd40l-specific tn3-derived scaffolds and methods of use thereof
EP2614846A4 (en) EMBODIENTS AND MANUFACTURING METHOD THEREFOR
GB201003531D0 (en) Composition and method
IL215720A0 (en) Dehumidifier and method of use thereof
GB201106433D0 (en) Composition and method
GB201008364D0 (en) Composition and method
PT3381462T (pt) Agente antiangiogénico e método de utilização de tal agente
GB201008843D0 (en) Method and composition
EP2859071A4 (en) CHEMICAL COMPOSITIONS AND METHODS OF USE
GB2482865B (en) Method of chapati and naan manufacture
GB201006582D0 (en) Container and method of manufacture therof
GB201021822D0 (en) Cleaning composition and method
GB201002278D0 (en) composition and method of preparation